Market Research Logo

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

The company’s recent market study titled 'Benign Prostatic Hyperplasia Prostate Treatment Market: Global Industry Analysis 2013-2017 & Opportunity Assessment 2018-2028' comprises a comprehensive assessment of the key market dynamics. Through detailed research on the growth parameters of the benign prostatic hyperplasia prostate treatment market, growth forecasts of the market have been obtained with maximum accuracy.

The report features exclusive and significant factors that have a huge impact on the development of the benign prostatic hyperplasia prostate treatment market during the forecast period. These factors can aid market players in developing marketing and manufacturing strategies, and visualize maximum growth in the benign prostatic hyperplasia prostate treatment market during the forecast years. The report offers thorough information about the growth prospects of the benign prostatic hyperplasia prostate treatment market in a comprehensive way for a better understanding of readers.

Chapter 1 – Executive Summary

The report begins with the executive summary of the benign prostatic hyperplasia prostate treatment market, which includes a detailed summary of the key findings, statistics, and technology roadmap of the market. It also includes the market value (US$ million) estimations of leading segments in the benign prostatic hyperplasia prostate treatment market.

Chapter 2 – Market Introduction and Overview

The report summaries the detailed taxonomy and definitions, which are key to understanding the basic information regarding the benign prostatic hyperplasia prostate treatment market dynamics, key players, pricing analysis, and regulation policies of this market.

Chapter 3 – Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 by Treatment Type

Based on treatment type, the benign prostatic hyperplasia prostate treatment market has been segmented into drugs and devices. The drugs segment of the benign prostatic hyperplasia prostate treatment market is segmented into alpha-blockers, alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs. The devices segment in the benign prostatic hyperplasia prostate treatment market is segmented into prostatic stents, suture base implant systems, and transurethral RF thermal therapy. Readers can find detailed information regarding the key market trends, developments, and market attractive analysis of the benign prostatic hyperplasia prostate treatment market based on treatment type.

Chapter 4 – Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 by Distribution Channel

In terms of the distribution channel, the benign prostatic hyperplasia prostate treatment market is segmented into institutional sales, retail sales, and online pharmacies. Further, the institutional sales segment is sub-segmented into hospitals, ambulatory surgical centers, and specialty clinics. The retail sales segment is sub-segmented into retail pharmacies and drug stores.

Chapter 5 – Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 by Region

This chapter provides detailed information regarding the current growth scenario of the benign prostatic hyperplasia prostate treatment market across various geographic regions such as North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa (MEA).

Chapter 6 – North America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes a detailed analysis of the North America benign prostatic hyperplasia prostate treatment market growth, along with a country-wise assessment, including the U.S. and Canada. Readers can find detailed information regarding regional trends, macroeconomic factors, and market growth based on treatment type, distribution channel, and country, in the North America benign prostatic hyperplasia prostate treatment market.

Chapter 7 – Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter consists of the growth forecasts for the Latin America benign prostatic hyperplasia prostate treatment market in leading countries such as Brazil, Mexico, and the Rest of Latin America. Readers can also find detailed information regarding factors such as pricing analysis, regional trends, and growth factors that are influencing the growth of the Latin America benign prostatic hyperplasia prostate treatment market.

Chapter 8 – Europe Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

In this chapter, readers can find detailed information regarding key growth forecasts of the benign prostatic hyperplasia prostate treatment market based on applications in various European countries such as the U.K., Germany, France, Italy, Spain, Russia, and the Rest of Europe.

Chapter 9 – South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes the growth prospects of the benign prostatic hyperplasia prostate treatment market in leading South Asian countries such as India, Thailand, Indonesia, Malaysia, and the Rest of South Asia.

Chapter 10 – East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes the growth prospects of the benign prostatic hyperplasia prostate treatment market in leading East Asian countries such as China, Japan, and South Korea.

Chapter 11 – Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

In this chapter, readers can find detailed information regarding several parameters influencing the Oceania benign prostatic hyperplasia prostate treatment market during the forecast period 2018-2028. Australia and New Zealand are the leading countries in Oceania that are the prime subjects of assessment to obtain the growth prospects of the Oceania benign prostatic hyperplasia prostate treatment market.

Chapter 12 – MEA Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

Readers can find thorough information regarding the growth factors that are impacting the MEA benign prostatic hyperplasia prostate treatment market, and gain insights on how the benign prostatic hyperplasia prostate treatment market is likely to impact the main countries/region in MEA, such as GCC Countries, Turkey, North Africa, South Africa, and the Rest of MEA, over the forecast period 2018-2028.

Chapter 13 – Competition Landscape, Company Share, and Company Profiles

This chapter provides readers a wide-ranging list of all the prominent key players in the benign prostatic hyperplasia prostate treatment market, along with detailed information regarding each company, including company overview, offered products, revenue shares, key strategy, and recent company developments.

Chapter 14 – Assumptions and Acronyms

This chapter in the benign prostatic hyperplasia prostate treatment market report includes a list of assumptions and acronyms that provide a base to the statistics and information included in the report.

Chapter 15 – Research Methodology

This chapter in the benign prostatic hyperplasia prostate treatment market report provides readers with a detailed research methodology employed to obtain various conclusions and important qualitative and quantitative information regarding the benign prostatic hyperplasia prostate treatment market.


1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. Technology Roadmap
1.4. FMI Analysis and Recommendations
2. Market Introduction
2.1. Market Introduction
2.2. Market Taxonomy
2.3. Market Definition
2.4. Inclusions and Exclusions
3. Benign Prostatic Hyperplasia Prostate Treatment Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Market Background
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Key Trends
5. Key Inclusions
5.1. Pipeline Analysis
5.2. Prevalence and Treatment Seeking Population Analysis
6. Global Economic Outlook
6.1. Gross Domestic Product by Region & Country, 2006 – 2021
7. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Region
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Trend Analysis by Region, 2013–2017
7.2.1. North America
7.2.2. Latin America
7.2.3. Europe
7.2.4. South Asia
7.2.5. East Asia
7.2.6. Oceania
7.2.7. The Middle East and Africa
7.2.8. Emerging Countries
7.3. Market Size (US$ Mn) Forecast By Region, 2018–2028
7.4. Market Attractiveness Analysis by Region
8. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Treatment Type
8.1. Introduction
8.2. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017
8.2.1. Drugs
8.2.1.1. Alpha Blockers
8.2.1.2. 5-alpha Reductase Inhibitors
8.2.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors
8.2.1.4. Muscarinic Receptor Antagonist (MRA)
8.2.1.5. Combination Drug
8.2.2. Device
8.2.2.1. Prostatic Stents
8.2.2.2. Suture Base Implant Systems
8.2.2.3. Transurethral RF Thermal Therapy Devices
8.3. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028
8.4. Market Attractiveness Analysis by Treatment Type
9. Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channels
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017
9.2.1. Institutional Sales
9.2.1.1. Hospital
9.2.1.2. Ambulatory Surgical Centers
9.2.1.3. Specialty Clinics
9.2.2. Retail Sales
9.2.2.1. Retail Pharmacies
9.2.2.2. Drug Stores
9.2.3. Online Pharmacies
9.3. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028
9.4. Market Attractiveness Analysis by Distribution Channels
10. North America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis by Country, 2013–2017
10.2.1. U.S.
10.2.2. Canada
10.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
10.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017
10.4.1. Drugs
10.4.1.1. Alpha Blockers
10.4.1.2. 5-alpha Reductase Inhibitors
10.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors
10.4.1.4. Muscarinic Receptor Antagonist (MRA)
10.4.1.5. Combination Drug
10.4.2. Device
10.4.2.1. Prostatic Stents
10.4.2.2. Suture Base Implant Systems
10.4.2.3. Transurethral RF Thermal Therapy Devices
10.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028
10.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017
10.6.1. Institutional Sales
10.6.1.1. Hospital
10.6.1.2. Ambulatory Surgical Centers
10.6.1.3. Specialty Clinics
10.6.2. Retail Sales
10.6.2.1. Retail Pharmacies
10.6.2.2. Drug Stores
10.6.3. Online Pharmacies
10.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028
10.8. Market Attractiveness Analysis
10.8.1. By Country
10.8.2. By Treatment Type
10.8.3. By Distribution Channel
10.9. Market Size and Forecast Factors
10.10. Key Intensity Mapping
11. Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028
11.1. Introduction
11.2. Historical Market Size (US$ Mn) By Country, 2013–2017
11.2.1. Brazil
11.2.2. Mexico
11.2.3. Rest of Latin America
11.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
11.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017
11.4.1. Drugs
11.4.1.1. Alpha Blockers
11.4.1.2. 5-alpha Reductase Inhibitors
11.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors
11.4.1.4. Muscarinic Receptor Antagonist (MRA)
11.4.1.5. Combination Drug
11.4.2. Device
11.4.2.1. Prostatic Stents
11.4.2.2. Suture Base Implant Systems
11.4.2.3. Transurethral RF Thermal Therapy Devices
11.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028
11.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017
11.6.1. Institutional Sales
11.6.1.1. Hospital
11.6.1.2. Ambulatory Surgical Centers
11.6.1.3. Specialty Clinics
11.6.2. Retail Sales
11.6.2.1. Retail Pharmacies
11.6.2.2. Drug Stores
11.6.3. Online Pharmacies
11.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028
11.8. Market Attractiveness Analysis
11.8.1. By Country
11.8.2. By Treatment Type
11.8.3. By Distribution Channel
11.9. Market Size and Forecast Factors
11.10. Key Intensity Mapping
12. Europe Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis by Country, 2013–2017
12.2.1. Germany
12.2.2. U.K.
12.2.3. France
12.2.4. Italy
12.2.5. Russia
12.2.6. Spain
12.2.7. Rest of Europe
12.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
12.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017
12.4.1. Drugs
12.4.1.1. Alpha Blockers
12.4.1.2. 5-alpha Reductase Inhibitors
12.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors
12.4.1.4. Muscarinic Receptor Antagonist (MRA)
12.4.1.5. Combination Drug
12.4.2. Device
12.4.2.1. Prostatic Stents
12.4.2.2. Suture Base Implant Systems
12.4.2.3. Transurethral RF Thermal Therapy Devices
12.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028
12.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017
12.6.1. Institutional Sales
12.6.1.1. Hospital
12.6.1.2. Ambulatory Surgical Centers
12.6.1.3. Specialty Clinics
12.6.2. Retail Sales
12.6.2.1. Retail Pharmacies
12.6.2.2. Drug Stores
12.6.3. Online Pharmacies
12.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028
12.8. Market Attractiveness Analysis
12.8.1. By Country
12.8.2. By Treatment Type
12.8.3. By Distribution Channel
12.9. Market Size and Forecast Factors
12.10. Key Intensity Mapping
13. South Asia Benign Prostatic Hyperplasia Prostate Treatment Analysis 2013–2017 and Forecast 2018–2028
13.1. Introduction
13.2. Historical Market Size (US$ Mn) By Country, 2013–2017
13.2.1. India
13.2.2. Thailand
13.2.3. Indonesia
13.2.4. Malaysia
13.2.5. Rest of South Asia
13.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
13.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017
13.4.1. Drugs
13.4.1.1. Alpha Blockers
13.4.1.2. 5-alpha Reductase Inhibitors
13.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors
13.4.1.4. Muscarinic Receptor Antagonist (MRA)
13.4.1.5. Combination Drug
13.4.2. Device
13.4.2.1. Prostatic Stents
13.4.2.2. Suture Base Implant Systems
13.4.2.3. Transurethral RF Thermal Therapy Devices
13.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028
13.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017
13.6.1. Institutional Sales
13.6.1.1. Hospital
13.6.1.2. Ambulatory Surgical Centers
13.6.1.3. Specialty Clinics
13.6.2. Retail Sales
13.6.2.1. Retail Pharmacies
13.6.2.2. Drug Stores
13.6.3. Online Pharmacies
13.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028
13.8. Market Attractiveness Analysis
13.8.1. By Country
13.8.2. By Treatment Type
13.8.3. By Distribution Channel
13.9. Market Size and Forecast Factors
13.10. Key Intensity Mapping
14. East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028
14.1. Introduction
14.2. Historical Market Size (US$ Mn) By Country, 2013–2017
14.2.1. China
14.2.2. Japan
14.2.3. South Korea
14.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
14.4. Historical Market Size (US$ Mn) Trend Analysis by Treatment Type, 2013–2017
14.4.1. Drugs
14.4.1.1. Alpha Blockers
14.4.1.2. 5-alpha Reductase Inhibitors
14.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors
14.4.1.4. Muscarinic Receptor Antagonist (MRA)
14.4.1.5. Combination Drug
14.4.2. Device
14.4.2.1. Prostatic Stents
14.4.2.2. Suture Base Implant Systems
14.4.2.3. Transurethral RF Thermal Therapy Devices
14.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028
14.6. Historical Market Size (US$ Mn) Trend Analysis by Distribution Channels, 2013–2017
14.6.1. Institutional Sales
14.6.1.1. Hospital
14.6.1.2. Ambulatory Surgical Centers
14.6.1.3. Specialty Clinics
14.6.2. Retail Sales
14.6.2.1. Retail Pharmacies
14.6.2.2. Drug Stores
14.6.3. Online Pharmacies
14.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028
14.8. Market Attractiveness Analysis
14.8.1. By Country
14.8.2. By Treatment Type
14.8.3. By Distribution Channel
14.9. Market Size and Forecast Factors
14.10. Key Intensity Mapping
15. Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028
15.1. Introduction
15.2. Historical Market Size (US$ Mn) By Country, 2013–2017
15.2.1. Australia
15.2.2. New Zealand
15.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
15.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2017
15.4.1. Drugs
15.4.1.1. Alpha Blockers
15.4.1.2. 5-alpha Reductase Inhibitors
15.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors
15.4.1.4. Muscarinic Receptor Antagonist (MRA)
15.4.1.5. Combination Drug
15.4.2. Device
15.4.2.1. Prostatic Stents
15.4.2.2. Suture Base Implant Systems
15.4.2.3. Transurethral RF Thermal Therapy Devices
15.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028
15.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017
15.6.1. Institutional Sales
15.6.1.1. Hospital
15.6.1.2. Ambulatory Surgical Centers
15.6.1.3. Specialty Clinics
15.6.2. Retail Sales
15.6.2.1. Retail Pharmacies
15.6.2.2. Drug Stores
15.6.3. Online Pharmacies
15.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028
15.8. Market Attractiveness Analysis
15.8.1. By Country
15.8.2. By Treatment Type
15.8.3. By Distribution Channel
15.9. Market Size and Forecast Factors
15.10. Key Intensity Mapping
16. MEA Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028
16.1. Introduction
16.2. Historical Market Size (US$ Mn) By Country, 2013–2017
16.2.1. GCC Countries
16.2.2. Turkey
16.2.3. South Africa
16.2.4. North Africa
16.2.5. Rest of MEA
16.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
16.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2017
16.4.1. Drugs
16.4.1.1. Alpha Blockers
16.4.1.2. 5-alpha Reductase Inhibitors
16.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors
16.4.1.4. Muscarinic Receptor Antagonist (MRA)
16.4.1.5. Combination Drug
16.4.2. Device
16.4.2.1. Prostatic Stents
16.4.2.2. Suture Base Implant Systems
16.4.2.3. Transurethral RF Thermal Therapy Devices
16.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028
16.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017
16.6.1. Institutional Sales
16.6.1.1. Hospital
16.6.1.2. Ambulatory Surgical Centers
16.6.1.3. Specialty Clinics
16.6.2. Retail Sales
16.6.2.1. Retail Pharmacies
16.6.2.2. Drug Stores
16.6.3. Online Pharmacies
16.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028
16.8. Market Attractiveness Analysis
16.8.1. By Country
16.8.2. By Treatment Type
16.8.3. By Distribution Channel
16.9. Market Size and Forecast Factors
16.10. Key Intensity Mapping
17. Emerging Countries Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013–2017 and Forecast 2018–2028
17.1. Introduction
17.2. Historical Market Size (US$ Mn) By Country, 2013–2017
17.2.1. China
17.2.2. Brazil
17.2.3. South Africa
17.3. Market Size (US$ Mn) Forecast By Country, 2018–2028
17.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013–2017
17.4.1. Drugs
17.4.1.1. Alpha Blockers
17.4.1.2. 5-alpha Reductase Inhibitors
17.4.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors
17.4.1.4. Muscarinic Receptor Antagonist (MRA)
17.4.1.5. Combination Drug
17.4.2. Device
17.4.2.1. Prostatic Stents
17.4.2.2. Suture Base Implant Systems
17.4.2.3. Transurethral RF Thermal Therapy Devices
17.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018–2028
17.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channels, 2013–2017
17.6.1. Institutional Sales
17.6.1.1. Hospital
17.6.1.2. Ambulatory Surgical Centers
17.6.1.3. Specialty Clinics
17.6.2. Retail Sales
17.6.2.1. Retail Pharmacies
17.6.2.2. Drug Stores
17.6.3. Online Pharmacies
17.7. Market Size (US$ Mn) Forecast By Distribution Channels, 2018–2028
17.8. Market Attractiveness Analysis
17.8.1. By Country
17.8.2. By Treatment Type
17.8.3. By Distribution Channel
17.9. Market Size and Forecast Factors
17.10. Key Intensity Mapping
18. Competitive Landscape
18.1. Competition Dashboard
18.2. Company Deep Dive
18.2.1. Pfizer, Inc.
18.2.1.1. Company Overview
18.2.1.2. Product Portfolio
18.2.1.3. Key Financials and Y-O-Y Growth
18.2.1.4. Key Development and Strategy
18.2.2. NxThera Inc.
18.2.2.1. Company Overview
18.2.2.2. Product Portfolio
18.2.2.3. Key Financials and Y-O-Y Growth
18.2.2.4. Key Development and Strategy
18.2.3. NeoTract, Inc.
18.2.3.1. Company Overview
18.2.3.2. Product Portfolio
18.2.3.3. Key Financials and Y-O-Y Growth
18.2.3.4. Key Development and Strategy
18.2.4. Sanofi S.A.
18.2.4.1. Company Overview
18.2.4.2. Product Portfolio
18.2.4.3. Key Financials and Y-O-Y Growth
18.2.4.4. Key Development and Strategy
18.2.5. GlaxoSmithKline plc.
18.2.5.1. Company Overview
18.2.5.2. Product Portfolio
18.2.5.3. Key Financials and Y-O-Y Growth
18.2.5.4. Key Development and Strategy
18.2.6. Allergan plc.
18.2.6.1. Company Overview
18.2.6.2. Product Portfolio
18.2.6.3. Key Financials and Y-O-Y Growth
18.2.6.4. Key Development and Strategy
18.2.7. Teva Pharmaceutical Industries Ltd
18.2.7.1. Company Overview
18.2.7.2. Product Portfolio
18.2.7.3. Key Financials and Y-O-Y Growth
18.2.7.4. Key Development and Strategy
18.2.8. Mylan N.V.
18.2.8.1. Company Overview
18.2.8.2. Product Portfolio
18.2.8.3. Key Financials and Y-O-Y Growth
18.2.8.4. Key Development and Strategy
18.2.9. Eli Lilly and Company
18.2.9.1. Company Overview
18.2.9.2. Product Portfolio
18.2.9.3. Key Financials and Y-O-Y Growth
18.2.9.4. Key Development and Strategy
18.2.10. Cardinal Health Inc.
18.2.10.1. Company Overview
18.2.10.2. Product Portfolio
18.2.10.3. Key Financials and Y-O-Y Growth
18.2.10.4. Key Development and Strategy
19. Assumptions and Acronyms Used
20. Research Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report